Explore our collection of case studies, webinars, and publications to learn more about what we do and what it’s like to work with us. If you need additional information or have specific questions, please let us know .
Case Studies
Learn how leading labs have used our Virology products to advance assay development for SARS-CoV-2, dengue, and other viruses.
Learn how dengue and Zika RVPs enabled clinical progression of Takeda’s Zika and dengue vaccines
Takeda required an alternative to traditional plaque‑reduction neutralization tests, which created bottlenecks in their Zika and dengue vaccine studies due to low throughput and high labor demands. Integral Molecular’s validated Reporter Virus Particles (RVPs) provided precise, reproducible neutralization data that aligned closely with live‑virus PRNT results while supporting the scale needed for multi‑serotype dengue and Zika ADE and immunogenicity testing. Because flavivirus RVPs are replication‑incompetent and quality‑controlled for use in standard BSL‑2 labs, they offered a reliable and efficient platform for advancing Takeda's dengue and Zika clinical programs.
-0.jpg){kind=small}
Learn how SARS-CoV-2 RVPs enabled Immunome to test their antibody cocktail and progress their therapeutic into the clinic
Immunome needed a safe, scalable way to test their three‑antibody SARS‑CoV‑2 therapeutic against rapidly evolving viral variants. Using Integral Molecular’s lentiviral Reporter Virus Particles, they rapidly characterized neutralization across more than 70 pseudotyped variants under BSL‑2 conditions, with results aligning closely to live‑virus assays. This breadth of variant coverage enabled Immunome to meet FDA expectations for continuous variant monitoring while advancing their therapeutic with confidence in its robustness.
.png){kind=logo}
SARS-CoV-2 RVPs and live virus show similar neutralization titers
Researchers at the University of Pittsburgh developing SARS‑CoV‑2 therapeutics required a rapid, BSL‑2‑compatible method to screen large panels of nanobodies for neutralizing activity without relying solely on live‑virus assays. Integral Molecular’s Reporter Virus Particles enabled high‑throughput evaluation of candidate nanobodies and streamlined selection of those with exceptional potency. These RVP‑based results closely aligned with plaque‑reduction neutralization tests lending confidence in assay relevance, while accelerating early therapeutic decision‑making.
.png){kind=small}
Learn how RVPs can be used for sera screening and immunogenicity assays
Immunogenicity testing for COVID‑19 vaccines requires cost-effective, quantitative assays capable of handling thousands of samples, prompting developers to seek reliable alternatives to live‑virus methods . Integral Molecular’s SARS‑CoV‑2 Reporter Virus Particles enabled contract research organizations like PPD to build high‑throughput pseudovirus microneutralization assays that met stringent criteria for precision, linearity, and specificity . These validated assays supported vaccine clinical trials by providing consistent neutralization readouts aligned with global regulatory expectations .
Articles and Guides
Read in-depth virology articles and view guides for successful assays.
- Pseudovirus Neutralization Assays: a how-to guide for getting started
- Ebola and Marburg Pseudovirus Biology and Applications: BSL-2 safe solutions for fast, efficient ebolavirus research
- Ready Reporter Virus Kit™ Guide: Readout on the Agilent BioTek Cytation 5
Webinars and Videos
Learn from the experts about characterizing viral vaccines and antibodies.
Webinar: Innovative Research Tools to Combat Biological Threats
Explore tools to enable safe, high‑throughput characterization of emerging viral threats without relying on live pathogens. This webinar describes practical strategies for evaluating variant biology, mapping antibody responses, and streamlining vaccine or therapeutic development using rigorously validated, BSL‑2‑compatible reagents.
Webinar: Reporter Virus Tools to Combat Current Viral Threats and the Next Pandemic
The webinar features experts from Integral Molecular, GigaGen, and Sanofi who demonstrate how Reporter Virus Particles enable safe, BSL‑2 neutralization assays for rapidly evolving pathogens and describe preclinical research on SARS-CoV-2 therapeutics. Viewers learn variant‑aware assay strategies and see how leading organizations accelerate antibody and vaccine development using extensive, customizable RVP panels.
Webinar: Combating SARS-CoV-2 Variants: Neutralization Testing from Alpha to Mu
The webinar demonstrates how SARS‑CoV‑2 variant Reporter Virus Particles enable rapid, BSL‑2 neutralization testing across Alpha–Mu variants, helping scientists from Immunome and the University of Pittburgh evaluate antibody and vaccine responses efficiently and meet evolving FDA recommendations for variant assessment.
Featured Publications
Read peer-reviewed publications describing the applications of Reporter Virus Particles and other Integral Molecular products.
Flavivirus - Zika and DENV
A high throughput reporter virus particle microneutralization assay for quantitation of Zika virus neutralizing antibodies in multiple species Bohning et al. 2021 PLoS One 16, e0250516
To support their flavivirus vaccine programs across preclinical and clinical studies, Takeda optimized and reported performance characteristics of a fit-for-use high-throughput RVP neutralization assay for ZIKV. Neutralization assays produced comparable titers irrespective of serum species. Use of our non-replicative platform improved the precision of the assay and was highly concordant with PRNT.
Single dose of chimeric dengue-2/Zika vaccine candidate protects mice and non-human primates against Zika virus Baldwin et al. 2021 Nature Communications 12, 7320
In a paper published by the CDC and Takeda in Nature Communications, a live-attenuated ZIKV vaccine was developed to provide durable protection and genetic stability suitable for large-scale manufacturing. ZIKV RVPs were used to measure neutralizing antibody titers for over 6 months following vaccination. Neutralizing antibody titer kinetics were comparable to FRNT assays and all animals with detectable antibodies were protected against viral RNAmia following ZIKV challenge.
Identification of the Seven Critical Residues that Control ZIKV-DENV Cross-reactivity to Engineer a Non-cross-reactive ZIKV Vaccine Grinyo-Escuer et al. 2025 Cell Reports 44, 116098
Antibody-dependent enhancement can exacerbate disease during flavivirus infection and is therefore a significant concern for the development of a ZIKV vaccine. In a 2025 Cell Reports paper, we defined the critical residues that drive cross-reactive binding between DENV and ZIKV. We engineered a ZIKV immunogen that minimized cross-reactivity, and demonstrated by ADE assay that our immunogen greatly reduced cross-reactive binding while conferring near-complete protection fromin vivo lethal ZIKV challenge.
Antigenicity, stability, and reproducibility of Zika reporter virus particles for long-term applications Whitbeck et al. 2020 PLoS Neglected Tropical Diseases 14, e0008730
In response to the 2015 ZIKV outbreak, we leveraged our experience with dengue flaviviruses to develop Zika Reporter Virus Particles that are suitable for clinical trials. In a 2020 paper published in PLoS NTD, we charactized infectivity, neutralization, and enhancement assays with monoclonal antibodies and ZIKV-positive patient sera. These studies demonstrated reproducibility, stability, and high-throughput compatibility of ZIKV RVPs that are critical for large-scale, long-term immunogenicity studies.
Complete Protection in Macaques Conferred by Purified Inactivated Zika Vaccine: Defining a Correlate of Protection Young et al. 2020 Scientific Reports 10, 3488
Takeda needed to evaluate immunogenicity and efficacy of their purified inactivated Zika vaccine in their animal challenge model. Using our Zika RVPs, they not only tracked neutralizing antibody titers over the course of a year following vaccination, but were able to define a correlate of protection between neutralizing antibody titer and peak Zika vRNA load post-challenge. The correlate of protection defined in their animal model provide a potential immune marker that could predict clinical benefit and that could support Zika vaccine licensure. Immunogenicity studies for this vaccine continue to be performed and reported in the literature with our RVPs, providing valuable consistency across preclinical and clinical trials.
SARS-CoV-2
A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential Bird et al. 2024 Nature Communications 15, 274
Red Queen Therapeutics saw the potential of their stapled lipopeptides compounds to be stable and potent inhibitors of highly pathogenic viruses. Using Integral Molecular's optimized RVPs and neutralization assay protocols, they could iteratively optimize their compounds against a spectrum of SARS-CoV-2 variants, identifying a pan-coronavirus inhibitor. Additionally, our RVPs allowed them to design and test compounds against other highly pathogenic viruses and identified a nanomolar inhibitor of Nipah virus.
A Phase I/II clinical trial of intradermal, controllable self-replicating ribonucleic acid vaccine EXG-5003 against SARS-CoV-2 Koseki et al. 2023 Vaccines 11, 1767
Elixirgen Therapeutics developed a self-replicating RNA vaccine to improve the strength and durability of responses to SARS-CoV-2. For their phase I/II clinical trial, they used our optimized SARS-CoV-2 RVPs and 293T-hsACE2 target cells to test both short- and long-term neutralizing antibody titers, demonstrating a durable priming response in patients who had received their self-replicating RNA vaccine.
IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2 Nikitin et al. 2022 Science Immunology 7, eabl9943
Immunome sought to develop an antibody cocktail that had broad reactivity to SARS-CoV-2 variants and that would limit the possibility of escape mutants from current and prospective variants. Immunome demonstrated high concordance between Integral Molecular's Reporter Virus Particle assays and FRNT assays using live virus. Our catalog enabled Immunome to test breadth across 70 SARS-CoV-2 variants and to identify synergistic antibody combinations. Epitope mapping by Integral Molecular helped elucidate the mechanism of action of Immunome's powerful antibody cocktail, showing it bound 3 nonoverlapping epitopes of the spike trimer, leading to its dissociation.
Pan-SARS neutralizing responses after third boost vaccination in non-human primate immunogenicity model Kalnin et al. 2022 Vaccine 40, 1289-1298
Sanofi Pasteur needed to evaluate vaccine candidates against key SARS-CoV-2 variants of concern. They used our widely accepted Reporter Virus Particle neutralization assays to compare vaccination regimens. Their findings found a third vaccination to be key for eliciting broadly neutralizing antibodies.
Filovirus - Ebola
Convergence of a common solution for broad ebolavirus neutralization by glycan cap directed human antibodies Murin et al. 2021 Cell Reports 35, 108984
Antibodies that can broadly neutralize Ebolaviruses are a valuable therapeutic agent during outbreaks. In a collaboration between the Scripps Research Institute and Vanderbilt University Medical Center, epitope mapping at Integral Molecular identified key contact residues for antibodies isolated from Ebola survivor cohorts. This paper reported a mechanism behind broadly neutralizing and synergistic glycan cap antibodies to inform rational design of therapeutic antibody cocktails.